CryoCloud, a Utrecht, the Netherlands based biotech startup that developed a proprietary data analysis platform, closed a a €500k pre-seed funding round.

荷兰乌得勒支生物技术初创公司CryoCloud开发了专有数据分析平台，完成了一轮50万欧元的种子前融资。

The round was led by Nina Capital, with participation from Utrecht Health Seed Fund and ROM Utrecht Region.

本轮谈判由Nina Capital牵头，乌得勒支健康种子基金和罗姆乌得勒支地区参与。

Co-founded in 2021 by Robert Englmeier, Ilja Gubins, and Boy Persoon, CryoCloud provides a cloud-based cryoEM data analysis platform that enables the fast and scalable determination of 3D protein structures used for drug discovery. The company has progressed from its conceptual stages, through various accelerator programs, to the launch the analysis platform designed to allow scientists to determine protein structures experimentally and visualise relevant targets in their native or drug-bound state.

CryoCloud于2021年由Robert Englmeier，Ilja Gubins和Boy Persoon共同创立，它提供了一个基于云的cryoEM数据分析平台，可以快速且可扩展地确定用于药物发现的3D蛋白质结构。该公司已经从概念阶段，通过各种加速器项目，发展到推出分析平台，该平台旨在让科学家通过实验确定蛋白质结构，并在其天然或药物结合状态下可视化相关目标。

CryoCloud will use the funds to expand the capabilities of its platform.

CryoCloud将利用这些资金来扩展其平台的功能。